Training in Biomolecular Pharmacology

描述(申请人提供)：波士顿大学医学院生物分子药理学博士前项目于1990年启动，并于1997年获得NIGMS机构培训补助金。在随后十年的NIGMS支持下，这一大学范围内的项目蓬勃发展，为博士生提供了一个独特的学习环境，结合了创新的课程、跨学科的实验室轮换，以及通过连接波士顿大学两个校区的多个系来扩大论文研究的机会。学生从三个学术单元中的一个进入该项目：药理学和实验治疗学(PET)、生物医学工程(BME)和分子医学(MM)。BME和MM的项目实习生将体验一个综合课程，旨在提供丰富的药理学培训，并与各自学科的专门培训相协调，而PET的实习生则可以获得建立在核心药理学教师提供的研究和教育经验基础上的各种研究和教育经验。该课程强调基本的药理学原理以及管理生物活性分子相互作用的关键问题，新疗法的药物输送的挑战，动物模型及其与临床的相关性，以及现代药物发现的挑战。参与的教师最初是15人，现在是46人，他们贡献了重点领域的专业知识，包括神经药理学、血管和癌症药理学、基因组学、蛋白质组学、动物模型(转基因和行为)、结构生物学以及DMA、RNA和蛋白质化学。论文研究的地点也设在化学、生物学、心理学、神经病学和精神病学系。惠氏研究所与合作科学家的暑期实习已全面实施，职业指导和导师/领导机会吸引学员获得与他们未来在学术界和行业的药理学职业相关的高质量经验。自成立以来，已有42名学生得到了NIGMS项目的支持，该项目是首批为经过量化培训的BME学生提供接口，将他们的核心研究与药理学培训联系起来的项目之一。该计划继续这一使命，并通过培训具备将基础研究进展转化为药物的下一代领导者，使学生掌握推动药物发现、医学和全球健康未来所需的智力工具。

DESCRIPTION (provided by applicant): The predoctoral Program in Biomolecular Pharmacology at Boston University School of Medicine was initiated in 1990 and received this NIGMS Institutional Training Grant in 1997. In the ensuing ten years of NIGMS support, this university-wide program has flourished, providing a unique learning environment for doctoral students that combines an innovative curriculum, interdisciplinary laboratory rotations, and expanded opportunities for thesis research by bridging multiple departments across Boston University's two campuses. Students enter the program from one of three academic units: Pharmacology and Experimental Therapeutics (PET), Biomedical Engineering (BME), and Molecular Medicine (MM). Program trainees in BME and MM experience an integrated curriculum designed to provide enriched training in pharmacology that is coordinated with specialized training in their discipline while trainees in PET gain access to diverse research and educational experiences that build upon those provided by core pharmacology faculty. The curriculum stresses fundamental pharmacologic principles as well as key issues governing interactions of bioactive molecules, challenges of drug delivery for novel therapeutics, animal models and their relevance to the clinic, and the challenges for modern drug discovery. Participating faculty, originally fifteen and now forty-six, contribute expertise in focus areas including neuropharmacology, vascular and cancer pharmacology, genomics, proteomics, animal models (transgenic and behavioral), structural biology, and DMA, RNA, and protein chemistry. Sites for thesis research are also located in departments of Chemistry, Biology, Psychology, Neurology and Psychiatry. A summer internship with collaborating scientists at Wyeth Research has been fully implemented and career guidance and mentorship/leadership opportunities engage trainees with quality experiences that are relevant to their future careers in pharmacology both in academia and industry. Since inception, forty-two students have been supported by this NIGMS program that was one of the first to provide an interface for quantitatively trained BME students to link their core studies with training in pharmacological sciences. The program has continued this mission and expanded to position students with intellectual tools needed to advance drug discovery, medicine, and the future of global health by training the next generation of leaders equipped to translate basic research advances into medications.